Miscellaneous ePI Test
0.1.0 - CI Build
Miscellaneous ePI Test
0.1.0 - CI Build
Miscellaneous ePI Test, published by . This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/cander2/epi-test/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="8da11d29-85ba-4a37-8c13-590ec8a14e5d"/>
<meta>
<versionId value="1"/>
<lastUpdated value="2021-04-01T00:00:00.000Z"/>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="https://leaflet.healthcare/sid/doc"/>
<value value="0eb41b56-c544-46cd-bfde-4b75d1d8e9aa"/>
</identifier>
<type value="document"/>
<timestamp value="2021-04-01T00:00:00.000Z"/>
<entry>
<fullUrl value="urn:uuid:e1710ae7-5e90-4d25-a4c7-78cf5e1c3615"/>
<resource>
<Composition>
<id value="e1710ae7-5e90-4d25-a4c7-78cf5e1c3615"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_e1710ae7-5e90-4d25-a4c7-78cf5e1c3615"> </a><p><b>Generated Narrative: Composition</b><a name="e1710ae7-5e90-4d25-a4c7-78cf5e1c3615"> </a><a name="hce1710ae7-5e90-4d25-a4c7-78cf5e1c3615"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Resource Composition "e1710ae7-5e90-4d25-a4c7-78cf5e1c3615" (Language "en") </p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b style="color: maroon">Exception generating Narrative: unknown extension http://hl7.org/fhir</b></p></div>
</text>
<contained>
<Binary>
<id value="pfizer-logo"/>
<contentType value="image/jpeg"/>
<data
value="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"/>
</Binary>
</contained>
<extension url="http://hl7.org/fhir">
<valueReference>
<reference value="#pfizer-logo"/>
</valueReference>
</extension>
<version value="1"/>
<date value="2021-04-01T00:00:00.000Z"/>
<status value="final"/>
<identifier>
<system value="https://leaflet.healthcare/sid/composition"/>
<value value="Cbe29343d-b174-4e39-8a4f-559d2afda963"/>
</identifier>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/v1/lists/100000155531/terms/"/>
<code value="100000155538"/>
<display value="Package Leaflet"/>
</coding>
</type>
<subject>
<reference value="urn:uuid:363620e9-fcf2-4256-86b9-2a8beb20623d"/>
</subject>
<author>
<reference value="urn:uuid:d06c80b8-a049-4299-9064-0ac99fe7e436"/>
</author>
<title
value="Master Gulf Levant - Aromasin 25mg - tablets - PLD Jordan"/>
<section>
<title value="PACKAGE LEAFLET"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml">
<p style="text-align: center">
<img src="#pfizer-logo" alt="Pfizer Logo"/>
</p>
<p style="text-align: center">
<b>Aromasin®</b>
</p>
<p style="text-align: center">25 mg coated tablets.</p>
<p style="text-align: center">Exemestane</p>
<p style="text-align: center">Reference Market: Italy</p>
<p style="text-align: center">
<b>PACKAGE LEAFLET</b>
</p>
</div>
</text>
<section>
<title value="Package leaflet: Information for the user"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml">
<p style="text-align: center">
<b>Package leaflet: Information for the user</b>
</p>
<p style="text-align: center">
<b>Aromasin 25 mg coated tablets</b>
</p>
<p style="text-align: center">(Exemestane)</p>
<p>Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.</p>
<p>Keep this leaflet. You may need to read it again.</p>
<p>If you have any further questions, ask your doctor or pharmacist.</p>
<p>This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.</p>
<p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.</p>
<p><b>What is in this leaflet</b></p>
<ol>
<li>What Aromasin is and what it is used for</li>
<li>What you need to know before you take Aromasin</li>
<li>How to take Aromasin</li>
<li>Possible side effects</li>
<li>How to store Aromasin</li>
<li>Contents of the pack and other information</li>
</ol>
</div>
</text>
</section>
<section>
<title value="1. What Aromasin is and what it is used for"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml">
<p>Your medicine is called Aromasin. Aromasin belongs to a group of medicines known as aromatase inhibitors. These medicines interfere with a substance called aromatase, which is needed to make the female sex hormones, oestrogens, especially in postmenopausal women. Reduction in oestrogen levels in the body is a way of treating hormone dependent breast cancer.</p>
<p>Aromasin is used to treat hormone dependent early breast cancer in postmenopausal women after they have completed 2-3 years of treatment with the medicine tamoxifen.</p>
<p>
Aromasin is also used to treat hormone dependent advanced breast cancer in postmenopausal women when a different hormonal drug treatment has not worked well enough.
</p>
</div>
</text>
</section>
<section>
<title value="2. What you need to know before you take Aromasin"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"/>
</text>
<section>
<title value="Do not take Aromasin"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml">
<ul>
<li>if you are or have previously been allergic to exemestane (the active ingredient in Aromasin) or any of the other ingredients of this medicine (listed in section 6).</li>
<li>if you have <b>not</b> already been through ‘the menopause’, i.e. you are still having your monthly period.</li>
<li>if you are pregnant, likely to be pregnant or breast-feeding.</li>
</ul>
</div>
</text>
</section>
<section>
<title value="Warnings and precautions"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml">
<ul>
<li>
Talk to your doctor, pharmacist or nurse before taking Aromasin.
</li>
<li>
Before treatment with Aromasin, your doctor may want to take blood samples to make sure you have reached the menopause.
</li>
<li>
Routine checking of your vitamin D level will also be made before treatment, as your level may be very low in the early stages of breast cancer. You will be given vitamin D supplement if your levels are below normal.
</li>
<li>
Before taking Aromasin, tell your doctor if you have problems with your liver or kidneys.
</li>
<li>
Tell your doctor if you have a history or are suffering from any condition which affects the strength of your bones. Your doctor may want to measure your bone density before and during the treatment of Aromasin. This is because medicines of this class lower the levels of female hormones and this may lead to a loss of the mineral content of bones, which might decrease their strength.
</li>
</ul>
</div>
</text>
</section>
<section>
<title value="Other medicines and Aromasin"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml">
<p>
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.
</p>
<p>
Aromasin should not be given at the same time as hormone replacement therapy (HRT).
</p>
<p>
The following medicines should be used cautiously when taking Aromasin. Let your doctor know if you are taking medicines such as:
</p>
<ul>
<li>
rifampicin (an antibiotic),
</li>
<li>
carbamazepine or phenytoin (anticonvulsants used to treat epilepsy),
</li>
<li>
the herbal remedy St John’s Wort (Hypericum perforatum), or preparations containing it.
</li>
</ul>
<p>
<u>For those who carry out sports activities</u>: the use of the drug without therapeutic necessity constitutes doping and can however determine positivity to the tests antidoping.
</p>
</div>
</text>
</section>
<section>
<title value="Pregnancy and breast-feeding"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml">
<p>
Do not take Aromasin if you are pregnant or breast-feeding.
</p>
<p>
If you are pregnant or think you might be, tell your doctor.
</p>
<p>
Discuss contraception with your doctor if there is any possibility that you may become pregnant.
</p>
</div>
</text>
</section>
<section>
<title value="Driving and using machines"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml">
<p>
If you feel drowsy, dizzy or weak whilst taking Aromasin, you should not attempt to drive or operate machinery.
</p>
</div>
</text>
</section>
<section>
<title
value="Aromasin contains sucrose, sodium and methyl parahydroxybenzoate"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml">
<ul>
<li>
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.
</li>
<li>
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.
</li>
<li>
Aromasin contains a small amount of methyl parahydroxybenzoate, which may cause allergic reactions (possibly delayed), if this should happen please contact your doctor.
</li>
</ul>
</div>
</text>
</section>
</section>
<section>
<title value="3. How to take Aromasin"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml">
</div>
</text>
<section>
<title value="Adults and the elderly patients"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml">
<p>
Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.
</p>
<p>
Aromasin tablets should be taken by mouth after a meal at approximately the same time each day. Your doctor will tell you how to take Aromasin and for how long.
</p>
<p>The recommended dose is one 25 mg tablet daily.</p>
<p>
If you need to go to the hospital whilst taking Aromasin, let the medical staff know what medication you are taking.
</p>
</div>
</text>
</section>
<section>
<title value="Use in children"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml">
<p>
Aromasin is not suitable for use in children.
</p>
</div>
</text>
</section>
<section>
<title value="If you take more Aromasin than you should"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml">
<p>
If too many tablets are taken by accident, contact your doctor at once or go straight to the nearest hospital casualty department. Show them the pack of Aromasin tablets.
</p>
</div>
</text>
</section>
<section>
<title value="If you forget to take Aromasin"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml">
<p>
Do not take a double dose to make up for a forgotten tablet.
</p>
<p>
If you forget to take your tablet, take it as soon as you remember. If it is nearly time for the next dose, take it at the usual time.
</p>
</div>
</text>
</section>
<section>
<title value="If you stop taking Aromasin"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml">
<p>
Do not stop taking your tablets even if you are feeling well, unless your doctor tells you.
</p>
<p>
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
</p>
</div>
</text>
</section>
</section>
<section>
<title value="4. Possible side effects"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml">
<p>
Like all medicines, this medicine can cause side effects, although not everybody gets them.
</p>
<p>
Hypersensitivity, inflammation of the liver (hepatitis) and inflammation of the bile ducts of the liver which cause yellowing of the skin (cholestatic hepatitis) may occur. Symptoms include feeling generally unwell, nausea, jaundice (yellowing of the skin and eyes), itching, right sided abdominal pain and loss of appetite. Contact your doctor promptly to seek urgent medical advice if you think you have any of these symptoms.
</p>
<p>
In general, Aromasin is well tolerated and the following side effects observed in patients treated with Aromasin are mainly mild or moderate in nature. Most of the side effects are associated with a shortage of oestrogen (e.g. hot flushes).
</p>
<p>
<b>Very common: may affect more than 1 in 10 people</b>
</p>
<ul>
<li>
Depression
</li>
<li>
Difficulty sleeping
</li>
<li>
Headache
</li>
<li>
Hot flushes
</li>
<li>Dizziness</li>
<li>Nausea</li>
<li>Increased sweating</li>
<li>Muscle and joint pain (including osteoarthritis, back pain, arthritis and joint stiffness)</li>
<li>Tiredness</li>
<li>A reduction in the number of white blood cells</li>
<li>Abdominal pain</li>
<li>Elevated level of liver enzymes</li>
<li>Elevated level of a haemoglobin breakdown in the blood</li>
<li>Elevated level of a blood enzyme in the blood due to liver damage</li>
<li>Pain</li>
</ul>
<p>
<b>Common: may affect up to 1 in 10 people</b>
</p>
<ul>
<li>Loss of appetite</li>
<li>Carpal tunnel syndrome (a combination of pins and needles, numbness and pain affecting all of the hand except the little finger) or tingling/prickling of the skin</li>
<li>Vomiting (nausea), constipation, indigestion, diarrhoea</li>
<li>Hair loss</li>
<li>Skin rash, hives and itchiness</li>
<li>Thinning of bones which might decrease their strength (osteoporosis), leading to bone fractures (breaks or cracks) in some cases</li>
<li>Swollen hands and feet</li>
<li>A reduction in the number of platelets in the blood</li>
<li>Feeling of weakness</li>
</ul>
<p>
<b>Uncommon: may affect up to 1 in 100 people</b>
</p>
<ul>
<li>Hypersensitivity</li>
</ul>
<p>
<b>Rare: may affect up to 1 in 1,000 people</b>
</p>
<ul>
<li>A breakout of small blisters on an area of the skin in a rash</li>
<li>Drowsiness</li>
<li>Inflammation of the liver</li>
<li>Inflammation of the bile ducts of the liver which cause yellowing of the skin</li>
</ul>
<p>
<b>Not known frequency cannot be estimated from the available data</b>
</p>
<ul>
<li>
Low level of certain white blood cells in the blood
</li>
</ul>
<p>Changes in the amount of certain blood cells (lymphocytes) and platelets circulating in your blood, especially in patients with a pre-existing lymphopenia (reduced lymphocytes in the blood) may also be seen.</p>
</div>
</text>
<section>
<title value="Reporting of side effects"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml">
<p>
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine
</p>
</div>
</text>
</section>
</section>
<section>
<title value="5. How to store Aromasin"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml">
<ul>
<li>Keep this medicine out of the sight and reach of children.</li>
<li>Store below 30°C</li>
<li>Do not use Aromasin after the expiry date stated on the box and on the blister pack after "Exp." The expiry date refers to the last day of that month.</li>
<li>This medicine does not require special precautions for storage.</li>
</ul>
<p>
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.
</p>
</div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"/>
</text>
<section>
<title value="What Aromasin contains"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml">
<ul>
<li>The active ingredient is exemestane. Each coated tablet contains 25 mg of exemestane.</li>
<li>The other ingredients are: colloidal hydrated silica, crospovidone, hypromellose, magnesium stearate, mannitol, microcrystalline cellulose, sodium carboxymethyl starch (type A), polysorbate 80, polyvinyl alcohol, simethicone, macrogol 6000 sucrose, magnesium carbonate light, methyl parahydroxybenzoate (E218), cetyl esters wax, talc, carnauba wax, ethyl alcohol, shellac, titanium dioxide (E171) and iron oxides (E172).</li>
</ul>
</div>
</text>
</section>
<section>
<title
value="What Aromasin looks like and the contents of the pack"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml">
<p>
Aromasin tablets are coated, round, biconvex, whitish and marked with 7663 on one side.
</p>
<p>
Aromasin is available in blister packs containing 15, 20, 30, 90, 100 and 120 tablets.
</p>
<p>
Not all package sizes may be marketed.
</p>
</div>
</text>
</section>
<section>
<title value="Marketing Authorisation Holder and Manufacturer"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml">
<p>
<b>Marketing Authorisation Holder</b>
</p>
<p>
Pfizer Italia S.r.l., via Isonzo 71 – 04100 Latina
</p>
<p>
Italy.
</p>
<p>
<b>Manufacturer</b>
</p>
<p>
Pfizer Italia S.r.l
</p>
<p>
Località Marino del Tronto – 63100 Ascoli Piceno (AP) ,
</p>
<p>
Italy.
</p>
<p>
<b>This leaflet was updated in April 2021.</b>
</p>
</div>
</text>
</section>
<section>
<title value="This leaflet was last revised in April 2021."/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"/>
</text>
</section>
<section>
<title value="THIS IS A MEDICAMENT"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml">
<table>
<tr>
<td>
<p style="text-align: center">
<b>THIS IS A MEDICAMENT</b>
</p>
<p>Medicament is a product which affects your health and its consumption contrary to instructions is dangerous for you.</p>
<p>Follow strictly the doctor’s prescription, the method of use and the instructions of the Pharmacist who sold the medicament.</p>
<p>The doctor and the Pharmacist are experts in medicines, their benefits and risks.</p>
<p>Do not by yourself interrupt the period of treatment prescribe.</p>
<p>Do not repeat the same prescription without consulting your doctor.</p>
<p style="text-align: center">
<b>Keep all medicaments out of reach and sight of children</b>
</p>
<p>
<b>Council of Arab Health Ministers</b>
</p>
<p>
<b>Union of Arabic Pharmacists</b>
</p>
</td>
</tr>
</table>
</div>
</text>
</section>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl value="urn:uuid:d06c80b8-a049-4299-9064-0ac99fe7e436"/>
<resource>
<Organization>
<id value="d06c80b8-a049-4299-9064-0ac99fe7e436"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Organization-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="Organization_d06c80b8-a049-4299-9064-0ac99fe7e436"> </a><p><b>Generated Narrative: Organization</b><a name="d06c80b8-a049-4299-9064-0ac99fe7e436"> </a><a name="hcd06c80b8-a049-4299-9064-0ac99fe7e436"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Resource Organization "d06c80b8-a049-4299-9064-0ac99fe7e436" </p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Organization-uv-epi.html">Organization (ePI)</a></p></div><p><b>identifier</b>: <code>https://leaflet.healthcare/sid/organization</code>/UORG-100000484 (use: official)</p><p><b>active</b>: true</p><p><b>type</b>: Marketing Authorisation Holder <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (rmswi#220000000034)</span></p><p><b>name</b>: Pfizer Italia S.r.l</p><h3>Contacts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Address</b></td></tr><tr><td style="display: none">*</td><td>Pfizer Italia S.r.l., via Isonzo 71 – 04100 Latina(work)</td></tr></table></div>
</text>
<identifier>
<use value="official"/>
<system value="https://leaflet.healthcare/sid/organization"/>
<value value="UORG-100000484"/>
</identifier>
<active value="true"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="220000000034"/>
<display value="Marketing Authorisation Holder"/>
</coding>
</type>
<name value="Pfizer Italia S.r.l"/>
<contact>
<address>
<use value="work"/>
<type value="physical"/>
<text value="Pfizer Italia S.r.l., via Isonzo 71 – 04100 Latina"/>
<line value="via Isonzo 71"/>
<city value="Latina"/>
<postalCode value="04100"/>
<country value="IT"/>
</address>
</contact>
</Organization>
</resource>
</entry>
<entry>
<fullUrl value="urn:uuid:5dc2f09f-5987-4515-8616-e5afa704aade"/>
<resource>
<Organization>
<id value="5dc2f09f-5987-4515-8616-e5afa704aade"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Organization-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="Organization_5dc2f09f-5987-4515-8616-e5afa704aade"> </a><p><b>Generated Narrative: Organization</b><a name="5dc2f09f-5987-4515-8616-e5afa704aade"> </a><a name="hc5dc2f09f-5987-4515-8616-e5afa704aade"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Resource Organization "5dc2f09f-5987-4515-8616-e5afa704aade" </p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Organization-uv-epi.html">Organization (ePI)</a></p></div><p><b>identifier</b>: <code>https://leaflet.healthcare/sid/organization</code>/UORG-100000484 (use: official)</p><p><b>active</b>: true</p><p><b>type</b>: Marketing Authorisation Holder <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (rmswi#220000000034)</span></p><p><b>name</b>: Pfizer Italia S.r.l</p><h3>Contacts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Address</b></td></tr><tr><td style="display: none">*</td><td>Pfizer Italia S.r.l, Località Marino del Tronto – 63100 Ascoli Piceno (AP)(work)</td></tr></table></div>
</text>
<identifier>
<use value="official"/>
<system value="https://leaflet.healthcare/sid/organization"/>
<value value="UORG-100000484"/>
</identifier>
<active value="true"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="220000000034"/>
<display value="Marketing Authorisation Holder"/>
</coding>
</type>
<name value="Pfizer Italia S.r.l"/>
<contact>
<address>
<use value="work"/>
<type value="physical"/>
<text
value="Pfizer Italia S.r.l, Località Marino del Tronto – 63100 Ascoli Piceno (AP)"/>
<line value="Località Marino del Tronto"/>
<city value="AP"/>
<postalCode value="63100"/>
<country value="IT"/>
</address>
</contact>
</Organization>
</resource>
</entry>
<entry>
<fullUrl value="urn:uuid:363620e9-fcf2-4256-86b9-2a8beb20623d"/>
<resource>
<MedicinalProductDefinition>
<id value="363620e9-fcf2-4256-86b9-2a8beb20623d"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_363620e9-fcf2-4256-86b9-2a8beb20623d"> </a><p><b>Generated Narrative: MedicinalProductDefinition</b><a name="363620e9-fcf2-4256-86b9-2a8beb20623d"> </a><a name="hc363620e9-fcf2-4256-86b9-2a8beb20623d"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Resource MedicinalProductDefinition "363620e9-fcf2-4256-86b9-2a8beb20623d" </p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-MedicinalProductDefinition-uv-epi.html">MedicinalProductDefinition (ePI)</a></p></div><p><b>identifier</b>: <code>https://leaflet.healthcare/sid/product</code>/P9cc8e88b-d18b-464e-8481-8973feaad1bb</p><p><b>type</b>: Medicinal Product <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-medicinal-product-type.html">Medicinal Product Type</a>#MedicinalProduct)</span></p><p><b>domain</b>: Human use <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-medicinal-product-domain.html">Medicinal Product Domain</a>#Human)</span></p><p><b>status</b>: active <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-publication-status.html">PublicationStatus</a>#active)</span></p><p><b>statusDate</b>: 2021-04-01 00:00:00+0000</p><p><b>route</b>: Oral route <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (routeOfAdministration#26643006)</span></p><p><b>legalStatusOfSupply</b>: Medicinal product subject to medical prescription <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-legal-status-of-supply.html">Legal Status Of Supply</a>#100000072084)</span></p><p><b>classification</b>: Aromatase inhibitors <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (medicinal-product-classification#L02BG06)</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Aromasin® (exemestane) 25 mg coated tablets</p><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td>Italy <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (country#IT)</span></td><td>Italy <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (jurisdiction#IT)</span></td><td>English <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (all-languages#en)</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="https://leaflet.healthcare/sid/product"/>
<value value="P9cc8e88b-d18b-464e-8481-8973feaad1bb"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<statusDate value="2021-04-01T00:00:00.000Z"/>
<legalStatusOfSupply>
<coding>
<system value="http://hl7.org/fhir/legal-status-of-supply"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<classification>
<coding>
<system
value="http://hl7.org/fhir/ValueSet/medicinal-product-classification"/>
<code value="L02BG06"/>
<display value="Aromatase inhibitors"/>
</coding>
</classification>
<route>
<coding>
<system
value="http://hl7.org/fhir/uv/emedicinal-product-info/ValueSet/routeOfAdministration"/>
<code value="26643006"/>
<display value="Oral route"/>
</coding>
</route>
<name>
<productName value="Aromasin® (exemestane) 25 mg coated tablets"/>
<usage>
<country>
<coding>
<system value="http://hl7.org/fhir/ValueSet/country"/>
<code value="IT"/>
<display value="Italy"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="http://hl7.org/fhir/ValueSet/jurisdiction"/>
<code value="IT"/>
<display value="Italy"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="http://hl7.org/fhir/ValueSet/all-languages"/>
<code value="en"/>
<display value="English"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2022+ . Package hl7.fhir.uv.epi-test#0.1.0 based on FHIR 5.0.0. Generated 2024-04-04
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
